Drug developer CG Oncology to raise up to $306 mln in upsized IPO

Jan 23, 2024 · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected.

CouponFollow Extension

$306
OFF

Drug Developer CG Oncology To Raise Up To $306 Mln In Upsized IPO

4 weeks from now

Jan 23, 2024 · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected.

yahoo.com

$306
OFF

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

4 weeks from now

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

4 weeks from now

Jan 23, 2024 · Adds background, IPO detail in paragraphs 2-6. Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. …

nasdaq.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

4 weeks from now

Jan 23, 2024 · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected. The move …

marketscreener.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

yahoo.com

$380
OFF

CG Oncology Prices Larger-than-expected $380M IPO In Hopeful …

4 weeks from now

Jan 24, 2024 · Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to …

biopharmadive.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

4 weeks from now

Jan 23, 2024 · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

tradingview.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

$19.00
OFF

CG Oncology Inc. | IPOScoop

4 weeks from now

(Note: CG Oncology, Inc. upsized its IPO at pricing – to 20.0 million shares – up from its recently increased size of 17.0 million shares – and priced the IPO at $19.00 – $1.00 above the top of …

iposcoop.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

4 weeks from now

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

4 weeks from now

Jan 18, 2024 · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

6%
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

4 weeks from now

5 days ago · CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. ...

stockanalysis.com

FAQs about Drug developer CG Oncology to raise up to $306 mln in upsized IPO Coupon?

Why did CG Oncology raise $380 million in its IPO?

Cancer drug developer CG Oncology has raised $380 million in an initial public offering. The company sold 20 million shares in its offering — eight million more than it had expected — at $19 apiece, indicating strong demand from investors. ...

Will CG oncology raise $306 million?

… Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected. (Reporting by Niket Nishant in Bengaluru; Editing by Arun Koyyur) ...

Does CG oncology have a biotech IPO?

CG Oncology's initial public offering (IPO), the first by a biotech firm this year, sets the stage for other healthcare companies such as KKR-backed BrightSpring Health Services and Moderna-backed Metagenomi. Investment in biotech companies over the past two years has been a fraction of historical levels. ...

Has CG had an IPO?

CG’s road to an IPO is a sign of the times, as the company has had an IPO. The company raised $308 million before its offering, including a $105 million Series F “crossover” round that bridged it to the public markets. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

How much is CG oncology worth?

If the offering is priced at the top end of the indicated range, CG Oncology would be valued at $1.1 billion in the IPO. Morgan Stanley, Goldman Sachs, Cantor and LifeSci Capital are the underwriters. The company is seeking to list on the Nasdaq under the symbol "CGON". ...